nivolumab,cabozantinib,girentuximab
bms,esteve,prometheus,heidelberg pharmaceuticals
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'biomarker', 'cabo ', 'nivo', 'girentuximab', 'marker ', 'imab ']
tip - starlite 1: ph 1b/2 study of combo 177lu girentuximab + cabo and nivo in rx-na ve pts with adv ccrcc #gu23 up to 100 pts 177lu-girentuximab 1480 mbq/m2 every 12 weeks up to 3 cycles; starting w/ 2nd cycle, nivo + cabo added primary ep: cr 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday